MAR 04, 2015 10:22 AM PST

Human Antibodies Can Fight Lethal Marburg Virus

WRITTEN BY: Judy O'Rourke
Researchers at Vanderbilt University, the University of Texas Medical Branch at Galveston, and The Scripps Research Institute for the first time have shown how human antibodies can neutralize the Marburg virus, a close cousin to Ebola.

Their findings, published this week in two papers in the journal Cell, should speed development of the first effective treatment and vaccine against these often lethal viruses, says James Crowe Jr, MD, whose team at Vanderbilt isolated and characterized the antibodies.

The study by Vanderbilt investigators describing how human antibodies can neutralize the Marburg virus is the featured article on the cover of the journal Cell. Fruit bats like these are known to harbor the virus.

Some of the anti-Marburg antibodies also bound to Ebola Zaire, the viral strain responsible for the West African outbreak that since last spring has killed about 9,000 people and sickened more than 22,000, mainly in Guinea, Liberia, and Sierra Leone.

"The good news is, humans do make antibodies when they are infected that can kill these viruses ... which suggests that vaccines should work," says Crowe, Ann Scott Carell Professor and director of the Vanderbilt Vaccine Center.

Alex Bukreyev, PhD, professor at UTMB Galveston and co-senior author with Crowe on one of the papers, says the research has moved forward dramatically since 2012, when "it was unclear whether an infected person can develop an effective antibody response to these infections."

The search for the viral "Achilles' heel" began three years ago, when Crowe read about an American tourist who was hospitalized in early 2008 with a life-threatening illness after returning to the United States from Uganda, where she had visited a fruit bat cave. She was later diagnosed with Marburg virus infection, the only known case in the United States. Fruit bats are known to harbor the virus.

Crowe contacted the woman through her physician. From a sample of her blood, first author and graduate student Andrew Flyak and colleagues in Crowe's lab used a high-efficiency method to isolate for the first time human antibodies that bound a protein on the surface of the Marburg virus.

The ability of some of the antibodies to neutralize, or kill, Marburg virus was confirmed in the level 4 biosafety facility at UTMB's Galveston National Laboratory. No live virus is used in the research at Vanderbilt.

In a separate paper published in Cell, Erica Ollmann Saphire, PhD, and colleagues at The Scripps Research Institute in La Jolla, Calif, used X-ray crystallography methods to solve, for the first time, the structure of the Marburg virus bound to antibodies provided by the Crowe lab.

"Since we know where on the virus important antibodies bind, that tells us what needs to be in the vaccine," Crowe says.

Vanderbilt is partnering with companies, including Mapp Biopharmaceutical Inc, San Diego, to produce large quantities of Marburg and Ebola antibodies that could be used to provide short-term protection from infection, especially for health care workers and family members who may be exposed to the viruses.

Ebola and Marburg are highly lethal in part because it takes the body's immune system four to six weeks to mount an antibody response. Injecting antibodies prior to or in the first few days following exposure could prevent full-blown illness, he says.

Crowe says he hoped clinical safety and dosage trials, some of which may be conducted at Vanderbilt, could be completed by the end of the year.

Antibody treatments are expensive, however, in part because they must be repeated every three to four weeks. That's why efforts are under way to develop a vaccine, which triggers the body's own immune response lasting for years and in some cases a lifetime.

[Source: Vanderbilt University]
About the Author
  • Judy O'Rourke worked as a newspaper reporter before becoming chief editor of Clinical Lab Products magazine. As a freelance writer today, she is interested in finding the story behind the latest developments in medicine and science, and in learning what lies ahead.
You May Also Like
OCT 12, 2021
Immunology
Major Landmark in a 100-Year Search for a Malaria Vaccine
OCT 12, 2021
Major Landmark in a 100-Year Search for a Malaria Vaccine
In one of the greatest global health milestones of our time, the World Health Organization has approved the widespread d ...
NOV 08, 2021
Cell & Molecular Biology
Understanding How Problems in Bone Marrow Transplants Arise
NOV 08, 2021
Understanding How Problems in Bone Marrow Transplants Arise
The hematopoietic system is how new blood cells are formed; hematopoietic stem cells in bone marrow generate new hematop ...
DEC 09, 2021
Cannabis Sciences
Considering Cannabinoids as a COVID-19 Treatment
DEC 09, 2021
Considering Cannabinoids as a COVID-19 Treatment
Research suggests that Cannabis sativa-derived cannabinoids – such as cannabidiol (CBD), Δ9tetrahydrocannabi ...
DEC 30, 2021
Cell & Molecular Biology
Researchers Discover Immune Cell Subtype Linked to MS and Neuroinflammation
DEC 30, 2021
Researchers Discover Immune Cell Subtype Linked to MS and Neuroinflammation
We still don't know exactly what causes multiple sclerosis (MS), or many other disorders that involve inflammation in th ...
JAN 06, 2022
Immunology
Worryingly High Levels of Free Radicals in COVID Patients
JAN 06, 2022
Worryingly High Levels of Free Radicals in COVID Patients
  COVID-19 infections trigger widespread oxidative damage, says new research by scientists from the Baylor College ...
JAN 17, 2022
Cancer
High Fiber Diet Provides a Helpful Boost to Melanoma Treatment
JAN 17, 2022
High Fiber Diet Provides a Helpful Boost to Melanoma Treatment
Immune checkpoint inhibitors (ICIs) have become a promising new treatment for advanced cancers, including melanoma. Immu ...
Loading Comments...